Patent ID: 6344464
Filing Date: 2002-02-05
Classification: A61K,A61P

Abstract:
A method for the treatment of diseases which cause demyelination which comprises administering to a patient in need of such treatment an effective amount of a compound of formula (I): in which:R1 is a halogen or a CF3, (C1-C4)alkyl or (C1-C4)alkoxy group; Y is a nitrogen atom or a CH group; Zâ€² and Zâ€³ are each hydrogen or a (C1-C3)alkyl group, or one is hydrogen and the other is a hydroxyl group, or the two together are an oxo group; and Z is: a phenyl radical; a phenyl radical monosubstituted by a substituent X, X being: (a) a (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C7)carboxyalkyl, (C1-C4)alkoxycarbonyl(C1-C6)alkyl, (C3-C7)carboxyalkoxy or (C1-C4)alkoxycarbonyl(C1-C6)alkoxy group; (b) a group selected from (C3-C7)cycloalkyl, (C3-C7)cycloalkoxy, (C3-C7)cycloalkylmethyl, (C3-C7)cycloalkylamino and cyclohexenyl, it being possible for said group to be substituted by a halogen, hydroxyl, (C1-C4)alkoxy, carboxyl, (C1-C4)alkoxycarbonyl, amino or mono- or di-(C1-C4)alkylamino; or (c) a group selected from phenyl, phenoxy, phenylamino, Nâ€”(C1-C3)alkyl-phenylamino, phenylmethyl, phenylethyl, phenylcarbonyl, phenylthio, phenylsulfonyl, phenylsulfinyl and styryl, it being possible for said group to be monosubstituted or polysubstituted on the phenyl group by a halogen, CF3, (C1-C4)alkyl, (C1-C4)alkoxy, cyano, amino, mono- or di-(C1-C4)alkylamino, (C1-C4)acylamino, carboxyl, (C1-C4)alkoxycarbonyl, aminocarbonyl, mono- or di-(C1-C4)alkylaminocarbonyl, amino(C1-C4)alkyl, hydroxy(C1-C4)alkyl or halogeno(C1-C4)alkyl; a phenyl radical disubstituted by a substituent R2, R2 being a halogen or a hydroxyl, methyl, ethyl, (C3-C6)alkyl, (C1-C4)alkoxy or trifluoromethyl group, and by a substituent X, X being as defined above; a 1-naphthyl or 2-naphthyl radical; or a 1-naphthyl or 2-naphthyl radical substituted in the 5-, 6-, 7- and/or 8-positions by one or two hydroxyl groups, one or two (C1-C4)alkoxy groups or a 6,7-methylenedioxy group; or Zâ€³ is hydrogen and Z and Zâ€² are each independently an unsubstituted or mono-, di- or tri-substituted phenyl group, or one of its pharmaceutically acceptable salts and solvates.